Evolva expands collaboration with IFF
Under the four year agreement, IFF will fund research and development activities at Evolva, focused primarily on pathway discovery and yield stages of the programme through the scale-up and manufacturing phases. Evolva will receive an upfront payment as well as monthly research fees. Furthermore, Evolva will receive royalty on product sales based on both margin and volume.
Neil Goldsmith, CEO of Evolva, said “Our first project with IFF is progressing well and we are excited about extending the collaboration. It is clear our biosynthesis platform is delivering radically new products and processes. These have the potential to open up markets that were previously constrained by cost, production or supply chain factors.”
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.